This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.
This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.
Assessing extracellular vesicle (EV) PD-L1 via liquid biopsy is an attractive non-invasive approach, but its predictive efficacy is confounded by non-tumor-derived EV background. To overcome this limitation, a novel assay selectively captured tumor-derived EVs (TEX) using the tumor-specific glycoantigen TF-Ag-α in serum from 91 NSCLC patients undergoing anti-PD-1 therapy. While baseline levels showed moderate performance (AUC 0.76), dynamic fold changes after the first treatment cycle revealed a ~4.18-fold increase in responders and a ~20% decrease in non-responders. This dynamic on-treatment metric delivered superior predictive power with an AUC of 0.93 (sensitivity 0.95, specificity 0.80), substantially outperforming both total EV PD-L1 and conventional tissue PD-L1.
This study investigates the molecular and spatial mechanisms underlying CD8+ T-cell immune exclusion in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockade. Spatial CD8+ exclusion, defined by stroma-restricted T cells that fail to penetrate tumor nests, correlates with reduced objective response rates and shorter progression-free survival. Multi-omic integration—including GeoMx spatial transcriptomics, multiplex immunofluorescence, and bulk transcriptomics—revealed tumor-intrinsic defects in antigen-presentation machinery, specifically involving HLA class I genes and TAP1, along with uncoupled IFN-γ signaling. Concurrently, the excluded stroma is characterized by myofibroblastic cancer-associated fibroblasts and collagen-dense barriers, accompanied by CD8+ T cells displaying impaired metabolic activation and lower TCR diversity rather than classic exhaustion.
The randomized phase 3 HERON-Lung01 trial evaluated the efficacy and safety of ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate (ADC), compared with platinum-pemetrexed chemotherapy in 498 patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who progressed on prior EGFR tyrosine kinase inhibitor (TKI) therapy. At the prespecified interim analysis, ruzaltatug rezetecan significantly prolonged progression-free survival compared to chemotherapy (median 8.3 months vs 5.4 months; HR 0.47; p < 0.0001). The safety profile was manageable, with grade 3 or higher treatment-related adverse events occurring in 41% vs 39% of patients, predominantly hematological, and leading to treatment discontinuation in only 1% per arm. These findings establish ruzaltatug rezetecan as a promising post-TKI therapeutic option in advanced EGFR-mutated NSCLC.
The TRIDENT study is a post-hoc analysis of the phase III POSEIDON trial, which evaluated the addition of tremelimumab to durvalumab and chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). This analysis utilized machine learning models integrating clinical, genomic, and radiomic data to identify patients who would derive greater overall survival (OS) benefit from the addition of tremelimumab. Results showed that the top-ranked 50% of patients with nonsquamous tumors, as identified by the model, achieved a hazard ratio of 0.56 for OS. Factors such as KRAS and STK11 mutations, along with wild-type EGFR, FGFR3, and CDKN2A, were strongly associated with higher OS benefit.
The phase II ORCHARD platform study evaluated the efficacy and safety of osimertinib combined with carboplatin and pemetrexed in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib monotherapy. Among 31 treated patients, the confirmed objective response rate was 26%, with a median duration of response of 7.6 months. Median progression-free survival reached 5.6 months, while median overall survival was 10.9 months. Grade ≥ 3 adverse events occurred in 65% of patients, leading to treatment discontinuation in 23%. These findings suggest that continuing osimertinib alongside platinum-based doublet chemotherapy offers modest clinical benefit post-progression.
This phase 1-2 study investigated the safety and efficacy of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated advanced RAS-mutant non-small-cell lung cancer (NSCLC). Patients received daily oral doses ranging from 10 to 400 mg. Results indicated that 99% of patients experienced adverse events of any grade, and 54% had grade 3 or higher events, with common side effects including rash and diarrhea. Antitumor activity, assessed by objective response rate, was over 30% across the evaluated dose groups.
The Phase II ORCHARD study investigated resistance mechanisms to first-line osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Utilizing next-generation sequencing (NGS) on both tissue and plasma samples, the study characterized the molecular profile of tumors after progression. Resistance alterations were detected in 87% of samples, often multiple, involving genes such as TP53, MDM2/4, PI3K, SOX2, and MYC. These findings highlight the heterogeneity of resistance and provide a rationale for exploring combination therapies to improve patient outcomes.
This study investigates cell-free DNA (cfDNA) profiles in the cerebrospinal fluid (CSF) of patients with lung cancer brain metastases. Using nanopore single-molecule sequencing, researchers analyzed fragmentation, methylation, and hydroxymethylation patterns of cfDNA. Significant differences were observed between cancer patients and healthy controls, including enriched mono-nucleosome levels and higher mono-/trinucleosome ratios in cancer patients. Distinct methylation and hydroxymethylation profiles were also identified, with a significantly lower degree of hydroxymethylation in cancer patients. These findings suggest that CSF cfDNA exhibits unique characteristics that could serve as biomarkers for non-small cell lung cancer brain metastases.
This prospective translational study aims to identify integrated predictive and prognostic biomarkers (genomic, epigenomic, transcriptomic) from circulating tumor DNA (ctDNA) and tumor tissue for non-small cell lung cancer (NSCLC). The objective is to improve early detection, risk stratification, treatment selection and response prediction, and longitudinal monitoring. The project places a particular emphasis on reducing cancer inequities, especially within Māori communities in New Zealand. Methods include DNA sequencing, cfRRBS DNA methylation profiling, and RNA sequencing, with integrative bioinformatic analyses. Expected findings will support the development of sensitive, accessible, and equitable blood-based biomarkers for NSCLC detection and monitoring.
This multicenter real-world study investigated histologic transformation to small-cell lung cancer (SCLC) in EGFR-mutant non-small cell lung cancer (NSCLC) patients, an aggressive resistance mechanism to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The study included 59 patients and found that adding immunotherapy (atezolizumab, durvalumab) to carboplatin and etoposide (CE) after transformation was associated with significantly improved post-transformation overall survival (17.0 months versus 9.0 months with CE alone). These findings suggest that immunotherapy may be beneficial in this setting, challenging prior evidence. Systematic re-biopsy is highlighted as crucial to confirm transformation and guide treatment.
This study represents the largest to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving front-line osimertinib. Researchers analyzed data from patients within a U.S. clinical-genomic database. The findings indicated that the presence of either the EGFR L858R mutation or a TP53 co-mutation independently predicted inferior real-world progression-free survival (rwPFS) and overall survival (OS). Patients with both unfavorable alterations (EGFR L858R and mutant TP53) experienced the shortest survival, with a median rwPFS of 10.1 months and a median OS of 21.3 months. This risk stratification could assist in identifying patients who might benefit from novel trials or intensified therapies.
ProphDR is a novel interpretable deep learning model designed to predict cancer drug responses by integrating multi-omics data and drug structural information. The model employs hierarchical attention mechanisms, including a Criss-Cross Gene-level Multiomics Integration (CGMI) module and a cross-attention (CA) module to model drug-gene interactions. Evaluated on GDSC and CCLE datasets, ProphDR achieves state-of-the-art performance in predicting ln(IC50) values and classifying drug sensitivity. It also demonstrates strong generalizability, even for unseen drugs or cell lines, and generates biologically interpretable attention maps.
A study involving 5420 non-small cell lung cancer (NSCLC) cases investigated the prevalence and impact of coexisting driver genetic alterations. Coexisting mutations were found in 3.9% of tumors, more frequently in females, with KRAS and PIK3CA being the most common combination. Clonality analysis revealed KRAS and EGFR as initiating drivers, while PIK3CA, AKT1, and IDH1 were mostly secondary events. The presence of EGFR + KRAS mutations was significantly associated with worse overall survival in both early and advanced stages. These findings emphasize the importance of comprehensive genomic profiling for effective therapeutic management.
Results from the LIBRETTO-432 study indicate that adjuvant selpercatinib substantially improves event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC). This finding establishes selpercatinib as a new standard of care for this rare disease. Nevertheless, challenges persist regarding patient identification and access to RET fusion screening.
This Australian multicenter study, derived from the AURORA registry, analyzed real-world treatment sequencing and survival in 115 patients with ROS1-rearranged NSCLC between 2012 and 2025. It revealed that a majority of patients (74%) received a ROS1 inhibitor as first-line therapy, with increasing use of later-generation inhibitors. Median overall survival was 56 months, extending to 80 months for those treated with a later-generation ROS1 inhibitor in the first line. Brain metastases and high PD-L1 expression were associated with shorter overall survival.
The prospective, multicenter ELIOS study characterized acquired resistance mechanisms to first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). By analyzing paired tumor biopsies taken pre-treatment and post-progression, the study identified frequent alterations including MET amplification, CDKN2A/CDKN2B and MTAP deletions, and the EGFR C797S mutation. Proteogenomic analysis also revealed high TROP2 expression, irrespective of genetic alterations. The findings highlight the heterogeneous nature of resistance and the complementary utility of tissue and liquid biopsies for alteration detection. This study emphasizes the need for therapeutic strategies targeting multiple resistance pathways.
This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.
This single-center retrospective study assessed the clinical utility of comprehensive genomic profiling (CGP) in 108 patients with advanced or recurrent non-small cell lung cancer (NSCLC) after standard treatments. CGP detected druggable genetic aberrations in 37% of patients, with EGFR mutations being the most common. Resistance mechanisms were identified in nearly half of patients re-biopsied after targeted therapy. Although CGP-guided therapy was recommended for 35.2% of patients, only 16.6% received it, showing a trend towards prolonged overall survival for this subgroup. The study concludes that CGP can identify actionable mutations missed by conventional diagnostics, thus providing additional therapeutic opportunities in NSCLC.
This retrospective observational study, conducted using the Italian ATLAS Registry, evaluated the efficacy and safety of amivantamab in 119 patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Most patients had previously received platinum-based chemotherapy, with or without immunotherapy. Amivantamab, administered as a single agent in subsequent lines, demonstrated an objective response rate of 37.5%, a median progression-free survival of 9.6 months, and a median overall survival of 16.9 months. The safety profile was manageable, with grade 3-4 treatment-related adverse events reported in 10.9% of patients, confirming data from the CHRYSALIS trial in a heavily pretreated real-world population.
This phase 3 study, LIBRETTO-432, investigated the efficacy and safety of adjuvant selpercatinib in patients with early-stage (IB, II, or IIIA) RET fusion-positive non-small-cell lung cancer (NSCLC) after definitive therapy. Patients were randomized to receive selpercatinib or placebo for up to three years. The primary endpoint was event-free survival (EFS) in patients with stage II or IIIA disease. Results demonstrated a significant improvement in 2-year EFS with selpercatinib (92% vs 61% for stage II/IIIA, HR=0.17), with a similar trend across all stage IB-IIIA patients (94% vs 70%, HR=0.16). The safety profile was manageable, with elevated transaminases being the most common adverse events.
This multicenter retrospective Japanese study compared afatinib and osimertinib as first-line treatments for advanced or recurrent non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations. Weighted analyses revealed no significant differences in time to treatment failure or overall survival between the two EGFR-TKIs. While afatinib was associated with higher response rates and more frequent adverse events requiring dose reduction, subgroup analyses suggested differential treatment effects based on mutation subtype. Furthermore, subsequent immune checkpoint inhibitor-based regimens showed limited additional benefit.
This study characterized the molecular architecture of the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) with somatic BRCA1/2 mutations, using single-cell sequencing and multi-omics data. BRCA1/2 mutations are linked to increased genomic instability and poor prognosis, yet predict better clinical outcomes with immune checkpoint blockade (ICB) treatment. BRCA1 mutations correlate with an upregulated type I IFN/IFN-γ signature and CD8+ T cell activation, while BRCA2 mutations are associated with inflammatory responses and enhanced MHC-II antigen presentation, influencing CD4+ T cell differentiation. The study also identified tissue-resident memory T cell (Trm) subsets as predictors of ICB response and found that a cancer-promoting program activated by BRCA1 is vulnerable to histone deacetylase inhibitors.
This study evaluated the cost-effectiveness of selpercatinib as a first-line or second-line treatment compared to chemotherapy alone for advanced RET fusion-positive non-small cell lung cancer (NSCLC) from the perspective of US payers. A partitioned survival model was employed to compare clinical outcomes and costs. The findings indicated that selpercatinib, whether used first-line or second-line, was not deemed cost-effective at the current willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). To achieve cost-effectiveness, a substantial price reduction for selpercatinib (approximately 70-77%) would be required. The study concludes that further real-world evidence is needed to inform clinical and health policy decisions.
Homozygous MTAP loss is frequently observed in oncogene-driven non-small-cell lung cancers (NSCLC), particularly in EGFR, ALK, and RET altered subtypes. While this loss did not significantly impact the response to first-line targeted therapies, it creates a selective vulnerability to PRMT5 inhibitors. Preclinical studies demonstrated that the PRMT5 inhibitor BMS-986504 is active in MTAP-deleted NSCLC models and can enhance the efficacy of existing targeted therapies. These findings suggest a novel combined therapeutic strategy for NSCLC patients with MTAP loss.
This study modeled the cost-effectiveness of various genomic testing strategies for patients with advanced non-small-cell lung cancer (NSCLC) in Australia. It compared combinations of sampling methods (tissue biopsy, liquid biopsy) and molecular tests (single-gene, small, or large panels). Results indicated that large genomic panel strategies, while more expensive, yielded the highest gains in quality-adjusted life years (QALYs). The analysis concluded that these comprehensive genomic testing approaches are potentially cost-effective, despite a notable budget impact on the healthcare system.
The phase II ORCHARD study investigated the efficacy and safety of combining osimertinib with datopotamab deruxtecan (Dato-DXd) in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who had progressed on first-line osimertinib. Two Dato-DXd doses (4 mg/kg and 6 mg/kg) were evaluated. Both cohorts demonstrated clinical benefit, with objective response rates (ORR) of 43% and 36% respectively. Median progression-free survival (PFS) was 9.5 months for the 4 mg/kg dose and 11.7 months for 6 mg/kg, while median overall survival (OS) reached 19.8 months and 26.2 months. Although the 6 mg/kg dose was associated with higher toxicity, it was manageable, and this dose is suggested as the preferred starting dose given the overall benefit-risk profile.